ISPY1 Dataset Clause Samples

POPULAR SAMPLE Copied 1 times
ISPY1 Dataset. This dataset contains the clinical and MRI data from the ISPY1 clinical trial of patients with breast cancer2. The goal of this project was to improve the prediction of clinical outcomes to neoadjuvant chemotherapy in patients with breast cancer. Currently, most patients with breast cancer undergo neoadjuvant chemotherapy, which is aimed to reduce the tumor size (burden) before surgery to remove the tumor or the entire breast. Some of the patients response completely to the therapy and the patient does not present any residual tumor at the time of surgery. On the other hand, some patients have residual disease at the time of surgery and further treatment is required. Dataset Name ISPY1_Trial Owner organization This shared data set was provided by ▇▇▇▇▇ ▇▇▇▇▇▇, PhD and ▇▇▇▇ ▇▇▇▇▇▇, PhD from the Breast Imaging Research Program at UCSF, in collaboration with ▇▇▇▇▇, CALGB, the I-SPY TRIAL, and TCIA. Dataset description (informal meta-data) The dataset includes data about 222 patients treated for breast cancer including demographics, clinical measures and outcomes It is a dataset that was already available when the BOUNCE project started. The data will be explored for their potential to be used in the project for building an in-silico model for resilience prediction. Formal Meta-data There is a data dictionary available for the various columns used. Standards No specific standards have been followed. Origin The I-SPY TRIAL Language The data are numeric Size 13 KB Variety Fully structured Type Numeric Format Tabular format Velocity 1 CSV/XLS file 2 ▇▇▇▇▇://▇▇▇▇.▇▇▇▇▇/▇▇▇▇▇/ispy-1-trial Storage A copy of the data is available at the BOUNCE data infrastructure Quality High quality data, will not many missing values. In addition a quality and consistency check has already been performed by the owning institution. Example ▇▇▇▇▇://▇▇▇▇.▇▇▇▇▇/▇▇▇▇▇/ispy-1- trial/workspace/file?filename=clean_data_ISPY-1_clinica.csv Availability The whole dataset is available to the public through their download site. Through the BOUNCE platform, the data will not be made available to external entities. Availability after the end of the project The data will be available after the end of the BOUNCE project both internally in the BOUNCE platform for consortium members and through the original dataset’s website. Sharing mechanisms Data are accessible through the original data web site. Within BOUNCE data are accessible through the Data Access API by all partners for downloading, viewing,...
View SourceView Similar (2)
ISPY1 Dataset. This dataset contains the clinical and MRI data from the ISPY1 clinical trial of patients with breast cancer6. The goal of this project is to improve the prediction of clinical outcomes to neoadjuvant chemotherapy in patients with breast cancer. Currently, most patients with breast cancer undergo neoadjuvant chemotherapy, which is aimed to reduce the tumor size (burden) before surgery to remove the tumor or the entire breast. Some of the patients response completely to the therapy and the patient does not present any residual tumor at the time of surgery. On the other hand, some patients have residual disease at the time of surgery and further treatment is required. Table 9 presents the various fields of the dataset. Age Patient Age Numeric Race_id Patient Race  1=Caucasian  3=African American  4=Asian  5=Native Hawaiian/Pacific Islander  6=American Indian/Alaskan Native  50=Multiple race ERpos Estrogen Receptor Status (▇▇▇▇▇▇  0=Negative Score or Community  1=Positive determined), pre-treatment  2=Indeterminate PgRpos Progesterone Receptor Status  0=Negative (▇▇▇▇▇▇ Score or Community  1=Positive determined), pre-treatment  2=Indeterminate HR Pos Hormone Receptor Status, pre- treatment    0=Negative for both ER and PR 1=Positive if either ER or PR was Positive 2=Indeterminate if both ER and PR were Indeterminate Her2MostPos Her2 Status, pre-treatment,  0=Negative (replaced Her2CommPos, adding in Central Her2 IHC results for missing Community   1=Positive Blank= indeterminate or 4/6/2016) Status not done 6 ▇▇▇▇▇://▇▇▇▇.▇▇▇▇▇/▇▇▇▇▇/ispy-1-trial HR_HER2_CATEGORY 3-level HR/Her2 category pre-  1=HR Positive, Her2 treatment Negative  2=Her2 Positive  3=Triple Negative HR_HER2_STATUS 3-level HR/Her2 status pre- treatment    HRposHER2neg = HR Positive, Her2 Negative HER2pos = Her2 Positive TripleNeg =Triple Negative BilateralCa Does the patient have bilateral  0=No breast cancer prior to  1=Yes neoadjuvant therapy? Laterality Index Tumor Laterality:   1=Left  2=Right MRI LD: LD spans all disease present (inv & DCIS) even if there is intervening normal tissue Numeric (in mm) Baseline Timepoint 1= baseline Numeric 1-3d AC Timepoint 2= 1-3days after start of AC Numeric InterReg Timepoint 3= Inter-regimen Numeric PreSurg Timepoint 3= Inter-regimen Numeric SUBJECTID I-SPY ID de-identifies a patient’s CALGB and ACRIN ID Numeric DataExtractDt Date clinical data was downloaded from the CALGB database Date format Sstat Survival Status   7=A...
View Source

Related to ISPY1 Dataset

  • SERVICE MONITORING, ANALYSES AND ORACLE SOFTWARE 11.1 We continuously monitor the Services to facilitate Oracle’s operation of the Services; to help resolve Your service requests; to detect and address threats to the functionality, security, integrity, and availability of the Services as well as any content, data, or applications in the Services; and to detect and address illegal acts or violations of the Acceptable Use Policy. Oracle monitoring tools do not collect or store any of Your Content residing in the Services, except as needed for such purposes. Oracle does not monitor, and does not address issues with, non-Oracle software provided by You or any of Your Users that is stored in, or run on or through, the Services. Information collected by Oracle monitoring tools (excluding Your Content) may also be used to assist in managing Oracle’s product and service portfolio, to help Oracle address deficiencies in its product and service offerings, and for license management purposes. 11.2 We may (i) compile statistical and other information related to the performance, operation and use of the Services, and (ii) use data from the Services in aggregated form for security and operations management, to create statistical analyses, and for research and development purposes (clauses i and ii are collectively referred to as “Service Analyses”). We may make Service Analyses publicly available; however, Service Analyses will not incorporate Your Content, Personal Data or Confidential Information in a form that could serve to identify You or any individual. We retain all intellectual property rights in Service Analyses. 11.3 We may provide You with the ability to obtain certain Oracle Software (as defined below) for use with the Services. If we provide Oracle Software to You and do not specify separate terms for such software, then such Oracle Software is provided as part of the Services and You have the non-exclusive, worldwide, limited right to use such Oracle Software, subject to the terms of this Agreement and Your order (except for separately licensed elements of the Oracle Software, which separately licensed elements are governed by the applicable separate terms), solely to facilitate Your use of the Services. You may allow Your Users to use the Oracle Software for this purpose, and You are responsible for their compliance with the license terms. Your right to use any Oracle Software will terminate upon the earlier of our notice (by web posting or otherwise) or the end of the Services associated with the Oracle Software. Notwithstanding the foregoing, if Oracle Software is licensed to You under separate terms, then Your use of such software is governed by the separate terms. Your right to use any part of the Oracle Software that is licensed under the separate terms is not restricted in any way by this Agreement.

  • Data Encryption Contractor must encrypt all State data at rest and in transit, in compliance with FIPS Publication 140-2 or applicable law, regulation or rule, whichever is a higher standard. All encryption keys must be unique to State data. Contractor will secure and protect all encryption keys to State data. Encryption keys to State data will only be accessed by Contractor as necessary for performance of this Contract.

  • MSAA Indicator Technical Specification Document This Agreement shall be interpreted with reference to the MSAA Indicator Technical Specifications document.

  • Evaluation Software If the Software is an evaluation version or is provided to You for evaluation purposes, then, unless otherwise approved in writing by an authorized representative of Licensor, Your license to use the Software is limited solely for internal evaluation purposes in non-production use and in accordance with the terms of the evaluation offering under which You received the Software, and expires 90 days from installation (or such other period as may be indicated within the Software). Upon expiration of the evaluation period, You must discontinue use of the Software, return to an original state any actions performed by the Software, and delete the Software entirely from Your system and You may not download the Software again unless approved in writing by an authorized representative of Licensor. The Software may contain an automatic disabling mechanism that prevents its use after a certain period of time. RESTRICTIONS

  • Product Data Illustrations, standard schedules, performance charts, instructions, brochures, diagrams, and other information furnished by Developer to illustrate a material, product, or system for some portion of the Work.